| Literature DB >> 30216993 |
Natalia Yu Anisimova1, Nadezhda E Ustyuzhanina2, Maria I Bilan3, Fedor V Donenko4, Natalia A Ushakova5, Anatolii I Usov6, Mikhail V Kiselevskiy7, Nikolay E Nifantiev8.
Abstract
Immunosuppression derived after cytostatics application in cancer chemotherapy is considered as an adverse side effect that leads to deterioration of quality of life and risk of infectious diseases. A linear sulfated (1→3)-α-l-fucan M-Fuc prepared by chemical modification of a fucoidan isolated from the brown seaweed Chordaria flagelliformis, along with two structurally related synthetic sulfated oligosaccharides, were studied as stimulators of hematopoiesis on a model of cyclophosphamide immunosuppression in mice. Recombinant granulocyte colony-stimulating factor (r G-CSF), which is currently applied in medicine to treat low blood neutrophils, was used as a reference. Polysaccharide M-Fuc and sulfated difucoside DS did not demonstrate significant effect, while sulfated octasaccharide OS showed higher activity than r G-CSF, causing pronounced neutropoiesis stimulation. In addition, production of erythrocytes and platelets was enhanced after the octasaccharide administration. The assessment of populations of cells in blood and bone marrow of mice revealed the difference in mechanisms of action of OS and r G-CSF.Entities:
Keywords: cyclophosphamide; fucoidan; granulocyte colony-stimulating factor; hematopoiesis; immunosuppression; synthetic oligosaccharide
Mesh:
Substances:
Year: 2018 PMID: 30216993 PMCID: PMC6164909 DOI: 10.3390/md16090333
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Modified fucoidan M-Fuc [14] and related synthetic octasaccharide OS [15,16] and disaccharide DS [17,18].
Hematologic parameters of mice with cyclophosphamide (CPh)-induced immunosuppression after treatment with modified fucoidan M-Fuc, octasaccharide OS, disaccharide DS, and recombinant granulocyte colony-stimulating factor (r G-CSF) (Mean ± SD).
| Groups | WBC (×103/µL) | RBC (×106/µL) | Hemoglobin (g/dL) | Platelets (×103/µL) |
|---|---|---|---|---|
| Control | 6.7 ± 1.14 | 9.4 ± 0.45 | 16.6 ± 0.64 | 571.5 ± 54.71 |
|
| 2.4 ± 0.36 | 5.4 ± 0.07 | 11.3 ± 1.73 | 812.3 ± 46.35 |
| 1.9 ± 1.20 | 5.4 ± 2.95 | 10.2 ± 5.52 | 589.0 ± 350.06 | |
| 5.3 ± 0.93 | 9.1 ± 1.11 | 16.7 ± 2.33 | 1036.3 ± 104.29 | |
| 2.3 ± 1.82 | 4.7 ± 2.89 | 8.7 ± 5.47 | 389.6 ± 207.74 | |
| 3.7 ± 0.47 | 7.0 ± 0.77 | 13.0 ± 1.30 | 541.0 ± 44.20 |
Different populations of leucocytes in blood of mice with CPh-induced immunosuppression after treatment with M-Fuc, OS, DS, and r G-CSF (Mean ± SD).
| Groups | Neutrophils (×103/µL) | Monocytes (×103/µL) | Lymphocytes (×103/µL) |
|---|---|---|---|
| Control | 1.9 ± 0.21 | 0.5 ± 0.01 | 4.4 ± 1.32 |
|
| 0.4 ± 0.25 | 0.2 ± 0.12 | 1.5 ± 0.38 |
| 0.5 ± 0.39 | 0.2 ± 0.10 | 1.2 ± 0.71 | |
| 2.1 ± 0.88 | 0.5 ± 0.22 | 2.3 ± 0.02 | |
| 1.3 ± 1.22 | 0.1 ± 0.01 | 0.6 ± 0.32 | |
| 1.1 ± 0.74 | 0.4 ± 0.09 | 2.1 ± 0.47 |
Different subpopulations of lymphocytes in blood of mice with CPh-induced immunosuppression after treatment with M-Fuc, OS, DS, and r G-CSF.
| Groups | CD3+CD4+ (%) | CD3+CD8+ (%) | The Ratio CD4+/CD8+ | NK (%) |
|---|---|---|---|---|
| Control | 31 ± 0.7 | 16 ± 3.8 | 1.94 ± 0.28 | 1.3 ± 0.8 |
|
| 14 ± 3.4 | 16 ± 3.1 | 0.88 ± 0.10 | 2.1 ± 2.0 |
| 16 ± 3.0 | 15 ± 2.2 | 1.07 ± 0.10 | 0.4 ± 1.2 | |
| 29 ± 2.4 | 15 ± 4.1 | 1.93 ± 0.19 | 2.3 ± 1.1 | |
| 24 ± 2.8 | 17 ± 1.4 | 1.41 ± 0.07 | 1.3 ± 0.2 | |
| 22 ± 0.8 | 16 ± 2.1 | 1.38 ± 0.50 | 3.2 ± 1.1 |
Expression of CD11c and CD62p on the granulocytes of mice with CPh-induced immunosuppression after treatment with M-Fuc, OS, DS and r G-CSF.
| Groups | CD11c+ | CD62p+ | ||
|---|---|---|---|---|
| % |
| % |
| |
| Control | 44 ± 5.4 | - | 48 ± 2.7 | - |
|
| 68 ± 8.1 | 0.057 | 70 ± 6.8 | 0.029 |
| 27 ± 3.1 | 0.047 | 8 ± 2.4 | 0.001 | |
| 34 ± 6.2 | 0.278 | 38 ± 4.1 | 0.097 | |
| 22 ± 3.9 | 0.021 | 23 ± 2.5 | 0.002 | |
| 13 ± 7.5 | 0.02 | 14 ± 8.4 | 0.012 | |
The effect of the tested compounds on the functional activity of the blood granulocytes in mice with CPh-induced immunosuppression.
| Groups | ROS+ Cells | |||
|---|---|---|---|---|
| % |
| % |
| |
| Control | 32 ± 3.4 | - | 31 ± 1.6 | - |
|
| 54 ± 4.1 | 0.009 | 36 ± 0.1 | 0.026 |
| 57 ± 3.1 | 0.003 | 35 ± 1.4 | 0.119 | |
| 43 ± 6.2 | 0.181 | 29 ± 1.1 | 0.350 | |
| 52 ± 3.9 | 0.012 | 47 ± 1.8 | 0.001 | |
| 29 ± 3.5 | 0.056 | 51 ± 0.8 | 0.001 | |
Figure 2Content of progenitor cells CD34+ in bone marrow of mice with CPh-induced immunosuppression after treatment with M-Fuc, OS, DS and r G-CSF.
Figure 3Analysis of the bone marrow cells cycle in mice with CPh-induced immunosuppression after treatment by tested compounds: (a) positive control—intact mice; (b) negative control—CPh; (c) CPh + M-Fuc; (d) CPh + OS; (e) CPh + DS; (f) CPh + r G-CSF.
Different phases of the bone marrow cells of mice with CPh-induced immunosuppression after treatment with M-Fuc, OS, DS, and r G-CSF.
| Groups | G0/G1 (%) | S (%) | G2/M (%) |
|---|---|---|---|
| Control | 63 | 23 | 14 |
|
| 65 | 29 | 4 |
| 68 | 24 | 8 | |
| 47 | 28 | 25 | |
| 58 | 34 | 8 | |
| 60 | 32 | 8 |
Figure 4Morphology of the spleen of mice with CPh-induced immunosuppression after treatment with tested compounds (hematoxylin-eosin staining): (a) positive control—intact mice; (b) negative control—CPh; (c) CPh + M-Fuc; (d) CPh + OS; (e) CPh + DS; (f) CPh + r G-CSF. Original magnification ×400.